temozolomide has been researched along with Diarrhea in 7 studies
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma." | 9.41 | Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. ( Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R, 2021) |
| "Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations." | 8.02 | Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. ( Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S, 2021) |
| "The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor." | 6.74 | Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. ( Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH, 2009) |
| " We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma." | 5.41 | Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. ( Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R, 2021) |
| "Cabozantinib inhibits mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabozantinib to radiotherapy (RT) and temozolomide (TMZ) for patients with newly diagnosed high-grade glioma." | 5.22 | Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. ( Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY, 2016) |
| "Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations." | 4.02 | Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. ( Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S, 2021) |
| "The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor." | 2.74 | Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. ( Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH, 2009) |
| "We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors." | 2.73 | Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ( Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Salah, S | 1 |
| To, YH | 1 |
| Khozouz, O | 1 |
| Ismail, T | 1 |
| Yaser, S | 1 |
| Alnsour, A | 1 |
| Shahin, O | 1 |
| Sultan, I | 1 |
| Abuhijlih, R | 1 |
| Halalsheh, H | 1 |
| Abuhijla, F | 1 |
| Lewin, J | 1 |
| Elinzano, H | 1 |
| Toms, S | 1 |
| Robison, J | 1 |
| Mohler, A | 1 |
| Carcieri, A | 1 |
| Cielo, D | 1 |
| Donnelly, J | 1 |
| Disano, D | 1 |
| Vatketich, J | 1 |
| Baekey, J | 1 |
| Sturtevant, A | 1 |
| MacKinnon, K | 1 |
| Wood, R | 1 |
| Safran, H | 1 |
| Schiff, D | 1 |
| Desjardins, A | 2 |
| Cloughesy, T | 1 |
| Mikkelsen, T | 1 |
| Glantz, M | 1 |
| Chamberlain, MC | 1 |
| Reardon, DA | 2 |
| Wen, PY | 1 |
| Jakacki, RI | 1 |
| Hamilton, M | 1 |
| Gilbertson, RJ | 1 |
| Blaney, SM | 1 |
| Tersak, J | 1 |
| Krailo, MD | 1 |
| Ingle, AM | 1 |
| Voss, SD | 1 |
| Dancey, JE | 1 |
| Adamson, PC | 1 |
| Casey, DA | 1 |
| Wexler, LH | 1 |
| Merchant, MS | 1 |
| Chou, AJ | 1 |
| Merola, PR | 1 |
| Price, AP | 1 |
| Meyers, PA | 1 |
| Vredenburgh, JJ | 1 |
| Herndon, JE | 1 |
| Coan, A | 1 |
| Gururangan, S | 1 |
| Peters, KB | 1 |
| McLendon, R | 1 |
| Sathornsumetee, S | 1 |
| Rich, JN | 1 |
| Lipp, ES | 1 |
| Janney, D | 1 |
| Friedman, HS | 1 |
| Tentori, L | 1 |
| Leonetti, C | 1 |
| Scarsella, M | 1 |
| Muzi, A | 1 |
| Mazzon, E | 1 |
| Vergati, M | 1 |
| Forini, O | 1 |
| Lapidus, R | 1 |
| Xu, W | 1 |
| Dorio, AS | 1 |
| Zhang, J | 1 |
| Cuzzocrea, S | 1 |
| Graziani, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| BrUOG 329: Onivyde (Nanoliposomal Irinotecan) and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: A Phase IB/IIA Brown University Oncology Research Group Study[NCT03119064] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2017-11-30 | Terminated (stopped due to lack of response to study therapy) | ||
| Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097] | 82 participants (Actual) | Observational | 2014-04-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the maximum tolerated dose of nanoliposomal irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma. (NCT03119064)
Timeframe: Every two weeks for 4 weeks
| Intervention | mg/m^2 (Number) |
|---|---|
| All Participants | 50 |
"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT03119064)
Timeframe: Every 2 months on study treatment then very 3 months once treatment has stopped, until progression of disease up to 2 years.
| Intervention | participants (Number) | |
|---|---|---|
| Partial Response | Progressive Disease | |
| Dose 1 | 1 | 8 |
| Dose 2 | 1 | 2 |
Treatment emergent toxicities of nanoliposomal irinotecan with continuous low-dose temozolomide using CTCAE version 4.03, grades 2 through 4 (NCT03119064)
Timeframe: Baseline through 30 days post off study treatment
| Intervention | events (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | ALT/AST | Hypokalemia | Hypophosphatemia | Nausea | Fatigue | Diarrhea | Anorexia | Dehydration | Urticaria | |
| Dose 1 | 0 | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 1 |
| Dose 2 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 0 |
5 trials available for temozolomide and Diarrhea
| Article | Year |
|---|---|
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Topics: Administration, Metronomic; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; B | 2021 |
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Asparta | 2016 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; | 2008 |
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptotheci | 2009 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
2 other studies available for temozolomide and Diarrhea
| Article | Year |
|---|---|
Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diarrhea; Disease Prog | 2021 |
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; | 2006 |